H1 2026 Highlights

"Our excellent first-half performance demonstrates the strength of Ipsen's strategy, with all three therapeutic areas contributing to growth and the portfolio beyond Somatuline continuing to accelerate. Importantly, we have significantly strengthened our late-stage pipeline in the first half, with positive Phase III lifecycle management readouts for Dysport in episodic and chronic migraine, Iqirvo in primary biliary cholangitis alongside the completed acquisition of Memo Therapeutics AG and the proposed acquisition of Kartos Therapeutics."

David Loew, Chief Executive Officer

External innovation

KARTOS THERAPEUTICS
- Acq. navtemadlin

MEMO THERAPEUTICS AG
- Acq. potravitug

Therapeutic area growth[1] and geography breakdown

Neuroscience

Dysport (abobotulinumtoxinA) Aesthetics	€257m	*+19.6%*
Dysport (abobotulinumtoxinA) Therapeutics	€170m	*+13.8%*

Rare Disease

IQIRVO	€173m	*+209.7%*
Bylvay (odevixibat) 200 | 400 | 600 | 1200 mcg capsules	€120m	*+44.8%*



Oncology

Somatuline autogel (lanreotide)	€686m	*+21.0%*
CABOMETYX (cabozantinib) tablets	€351m	*+18.8%*
Decapeptyl (triptorelin)	€284m	*+3.5%*
onivyde (irinotecan liposome injection)	€108m	*+11.2%*

North America	Europe[2]	Rest of the World
36.3% of total sales	**37.6%** of total sales	**26.1%** of total sales

Pipeline progression

Three positive Phase III readouts:
- Dysport – C-BEOND & E-BEOND
- Iqirvo – ELSPIRE

Three late-stage starts supporting assets:
- Corabotase – Phase III in GL (LAURITE)
- Elafibranor – Phase III in PSC (ELASCOPE)
- IPN60340 – Phase II/III in 1L AML (EVICTION 3)

Upgraded FY 2026 guidance[3]

Total sales growth[4]
>20.0%
at constant exchange

Core operating margin[5]
>37.0%
of total sales

[1] At constant exchange rates; [2] Europe is defined as the E.U., the U.K., Iceland, Liechtenstein, Norway and Switzerland; **GL:** Glabellar Lines; **PSC:** Primary Sclerosing Cholangitis; **1L;** First-Line; **AML:** Acute Myeloid Leukemia; [3] Excluding any impact from potential late-stage (Phase III clinical development or later) external innovation transaction; [4] Based on the average level of exchange rates in June 2026, an adverse effect on total sales of around 1% of currencies is expected; [5] Including additional R&D expenses from anticipated early and mid-stage external-innovation opportunities

IPSEN
www.ipsen.com/investors

Henry Wheeler
Vice President
Investor Relations
+33 7 64 47 11 49
henry.wheeler@ipsen.com

Khalid Deojee
Senior Manager
Investor Relations
+33 6 66 01 95 26
khalid.deojee@ipsen.com